Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon Apr 04, 2023 3:10pm
134 Views
Post# 35379416

RE:RE:RE:ONC/Y and the FDA

RE:RE:RE:ONC/Y and the FDA
venture009 wrote: An AA is something we would all like but I don't think it's going to happen.  The FDA is in the BP back pocket and an AA wouldn't be in their best interest. 


Do you have specific knowledge of this in the case of ONC/Y, venture009?  I looked online for corruption/bribery issues involving FDA and only found a handful mentioned in the last five years or so.  FDA is overseeing thousands of trials a year.  I'd suggest it's a small problem.  

There is an issue with the pharma industry providing funding to FDA - there are legislators who think that creates a conflict of interest (and I agree with them) - current FDA budgets are funded about 75% by industry.  However, BP tends to act more through their lobbying group, and their lobbyists seem to spend more time restricting generic drug production.  What collusion I could find was to get new drugs approved rather than the opposite.    

In the case of ONC/Y, Pfizer/Merck/Roche would benefit either way - an AA would give them quite rapid access to an enlarged market for their partner drugs in the ONC/Y combo.  They'd likely make more money owning Pela, but they still make money from their own partner drugs in the Pela combos.  And they get a further 12 years' patent protection either way.



<< Previous
Bullboard Posts
Next >>